ESMO Congress 2024
Novel treatment strategies show potential activity in metastatic colorectal cancer
Preliminary results from three clinical trials reveal some benefits of cetuximab plus irinotecan, amivantamab plus FOLFOX or FOLFIRI and ramucirumab plus standard of care for patients with mCRC, including after progression on standard therapies
Mixed results reported for cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer
Final overall survival data from the CONTACT-02 study are negative, but a survival advantage was observed with the novel combination in patients with liver or bone metastasis
Radiopharmaceuticals boost the efficacy of androgen-receptor pathway inhibitors in metastatic castration-resistant prostate cancer
The first results from two phase III studies of Ra-223 and 177Lu-PNT2002 may help to decipher their role in the treatment of patients with mCRPC
Questions still remain on optimal adjuvant therapy in advanced melanoma
Overall survival benefits of systemic therapy in the adjuvant setting are still unclear in clinical trials, and may need to be complemented with real-world studies
Does artificial intelligence have a place in precision oncology?
Applications in artificial intelligence have the potential to transform precision oncology, but data quality and clinical validation of tools are still challenging
New data provide guidance to personalise treatment in recurrent and metastatic salivary gland cancer
Two studies report the results about the use of trastuzumab deruxtecan and androgen deprivation therapy for patients with this rare cancer
New insights into pleural mesothelioma
Studies reveal promising evidence for the more precise tailoring of immunotherapy and the role of AI in improving response evaluation
Future holds significant potential for advancement in immunotherapy of brain tumours
Results presented from some studies are a signal of an active area of research which is investigating not only immune checkpoint inhibitors but also vaccines and cellular therapies, although there are no immunotherapy treatments currently approved.
Study results further support the use of neoadjuvant immunotherapy in dMMR colon cancer
Three-year disease-free survival data from NICHE-2 and findings from NICHE-3 add to current knowledge on the benefits of immune checkpoint inhibition in this setting
Adding lenvatinib and pembrolizumab to transarterial chemoembolization improves progression-free survival in hepatocellular carcinoma
Positive data presented from the LEAP-012 study for intermediate-stage disease, but it is still unclear how these will influence clinical practice